ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit

Cancer Research

Volumn 74, Issue 15, 2014, Pages 4196-4207

  Wilson, Brian J ^a,b,c   Saab, Karim R ^a,b   Ma, Jie ^a,b   Schatton, Tobias ^a,b   Pütz, Pablo ^b   Zhan, Qian ^a   Murphy, George F ^a   Gasser, Martin ^d   Waaga Gasser, Ana Maria ^d   Frank, Natasha Y ^a,b,c   Frank, Markus H ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER B5; CHEMOKINE RECEPTOR CXCR1; INTERLEUKIN 1BETA; INTERLEUKIN 8; WNT PROTEIN; ABCB5 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE RELEASE; GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MELANOMA INITIATING CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; WFDC1 GENE; WNT SIGNALING PATHWAY; ANIMAL; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNOLOGY; MELANOMA; METABOLISM; MICROARRAY ANALYSIS; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION; HETEROGRAFTS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-8; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; MICROARRAY ANALYSIS; NEOPLASTIC STEM CELLS; P-GLYCOPROTEIN; RECEPTORS, INTERLEUKIN-8A; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84905454413     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0582     Document Type: Article

References (50)

1. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008;451:345-9.
2. Civenni G, Walter A, Kobert N, et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 2011;71:3098-109.
3. Kumar SM, Liu S, Lu H, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012;31:4898-911.
4. Kupas V, Weishaupt C, Siepmann D, et al. RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol 2011;131:944-55.
5. Linley AJ, Mathieu MG, Miles AK, Rees RC, McArdle SE, Regad T. The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo. J Biol Chem 2012;287:13633-43.
6. Cheung ST, Cheung PF, Cheng CK, Wong NC, Fan ST. Granulinepithelin precursor and ATP-dependent binding cassette (ABC) B5 regulate liver cancer cell chemoresistance. Gastroenterology 2011;140:344-55.
7. Wilson BJ, Schatton T, Zhan Q, et al. ABCB5 identifies a therapyrefractory tumor cell population in colorectal cancer patients. Cancer Res 2011;71:5307-16.
8. Chartrain M, Riond J, Stennevin A, et al. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One 2012;7:e36762.
9. Ma J, Lin JY, Alloo A, et al. Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 2010;402:711-7.
10. Gazzaniga P, Cigna E, Panasiti V, et al. CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients. Eur J Surg Oncol 2010;36:1211-4.
11. Sharma BK, Manglik V, Elias EG. Immuno-expression of human melanoma stem cell markers in tissues at different stages of the disease. J Surg Res 2010;163:e11-5.
12. Setia N, Abbas O, Sousa Y, Garb JL, Mahalingam M. Profiling of ABC transporters ABCB5, ABCF2 and nestin-positive stem cells in nevi, in situ and invasive melanoma. Mod Pathol 2012;25:1169-75.
13. Boiko AD, Razorenova OV, van de Rijn M, et al. Human melanomainitiating cells express neural crest nerve growth factor receptor CD271. Nature 2010;466:133-7.
14. Boonyaratanakornkit JB, Yue L, Strachan LR, et al. Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol 2010;130:2799-808.
15. Frank NY, Schatton T, Kim S, et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2011;71:1474-85.
16. Fukunaga-Kalabis M, Martinez G, Nguyen TK, et al. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 2010;29:6115-24.
17. Schatton T, Schutte U, Frank NY, et al. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 2010;70:697-708.
18. Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A 2011;108:2474-9.
19. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65:4320-33.
20. Murphy GF, Wilson BJ, Girouard SD, Frank NY, Frank MH. Stem cells and targeted approaches to melanoma cure. Mol Aspects Med 2013.
21. Shakhova O, Sommer L. Testing the cancer stem cell hypothesis in melanoma: the clinics will tell. Cancer Lett 2013;338:74-81.
22. Quintana E, Shackleton M, Foster HR, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010;18:510-23.
23. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-8.
24. Reid AL, Millward M, Pearce R, et al. Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol 2013;168:85-92.
25. Lin JY, Zhang M, Schatton T, et al. Genetically determined ABCB5 functionality correlates with pigmentation phenotype and melanoma risk. Biochem Biophys Res Commun 2013;436:536-42.
26. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41-50.
27. Frank NY, Pendse SS, Lapchak PH, et al. Regulation of progenitor cell fusion by ABCB5P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 2003;278:47156-65.
28. Luo Y, Ellis LZ, Dallaglio K, et al. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol 2012;32:2440-50.
29. Madar S, Brosh R, Buganim Y, et al. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis 2009;30:20-7.
30. Liu S, Howell P, Ren S, et al. Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma. Clin Exp Metastasis 2009;26:739-49.
31. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001;19:577-83.
32. Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002;161:125-34.
33. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003;2:753-63.
34. Lev DC, Onn A, Melinkova VO, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004;22:2092-100.
35. Levy L, Neuveut C, Renard CA, et al. Transcriptional activation of interleukin-8 by b-catenin-Tcf4. J Biol Chem 2002;277:42386-93.
36. Masckauchan TN, Shawber CJ, Funahashi Y, Li CM, Kitajewski J. Wnt/b-catenin signaling induces proliferation, survival and interleukin-8 in human endothelial cells. Angiogenesis 2005;8:43-51.
37. Varney ML, Li A, Dave BJ, Bucana CD, Johansson SL, Singh RK. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis 2003;20:723-31.
38. Singh S, Nannuru KC, Sadanandam A, Varney ML, Singh RK. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 2009;100:1638-46.
39. Ginestier C, Liu S, Diebel ME, et al. CXCR1blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485-97.
40. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006;4:48.
41. Zhou X, Engel T, Goepfert C, Erren M, Assmann G, von Eckardstein A. The ATP binding cassette transporter A1 contributes to the secretion of interleukin 1b from macrophages but not from monocytes. Biochem Biophys Res Commun 2002;291:598-604.
42. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010;141:583-94.
43. Botelho MG, Wang X, Arndt-Jovin DJ, Becker D, Jovin TM. Induction of terminal differentiation in melanomacells on downregulation of b-amyloid precursor protein. J Invest Dermatol 2010;130:1400-10.
44. Arce C, Perez-Plasencia C, Gonzalez-Fierro A, et al. A proof-ofprinciple study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006;1:e98.
45. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13.
46. +) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012;55:807-20.
47. Varney ML, Singh S, Li A, Mayer-Ezell R, Bond R, Singh RK. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett 2010;300:180-8.
48. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009;86:557-66.
49. Berking C, Takemoto R, Satyamoorthy K, et al. Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res 2004;64:807-11.
50. Lewis W, Simanyi E, Li H, et al. Regulation of ultraviolet radiation induced cutaneous photoimmunosuppression by toll-like receptor-4. Arch Biochem Biophys 2011;508:171-7.